M R Alderson

Summary

Affiliation: Corixa Corporation
Country: USA

Publications

  1. ncbi Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells
    M R Alderson
    Department of Immunology, Corixa Corporation, Seattle, Washington 98104, USA
    J Exp Med 191:551-60. 2000
  2. ncbi Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:2941-50. 1999
  3. ncbi Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 38:3285-90. 2000
  4. ncbi Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
  5. ncbi Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:3998-4007. 1999
  6. ncbi Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis
    J R Webb
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 66:4208-14. 1998
  7. ncbi Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells
    D M Lewinsohn
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington 98104, USA
    J Exp Med 187:1633-40. 1998
  8. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
  9. ncbi CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 160:2037-41. 1998
  10. ncbi Fas and FasL in the homeostatic regulation of immune responses
    D H Lynch
    Immunex Corporation, Seattle, WA 98101, USA
    Immunol Today 16:569-74. 1995

Collaborators

Detail Information

Publications18

  1. ncbi Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells
    M R Alderson
    Department of Immunology, Corixa Corporation, Seattle, Washington 98104, USA
    J Exp Med 191:551-60. 2000
    ..9A. The direct identification of antigens using T cells from immune donors will undoubtedly be critical for the development of vaccines to several intracellular pathogens...
  2. ncbi Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:2941-50. 1999
    ..The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M.tuberculosis...
  3. ncbi Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG
    D C Dillon
    Corixa Corporation, Seattle, Washington 98104, USA
    J Clin Microbiol 38:3285-90. 2000
    ..rCFP-10 could also contribute to the development of a recombinant T-cell diagnostic test capable of detecting exposure to M. tuberculosis...
  4. ncbi Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
    R N Coler
    The Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 166:6227-35. 2001
    ..tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB...
  5. ncbi Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis
    Y A Skeiky
    Corixa Corporation, Seattle, Washington 98104, USA
    Infect Immun 67:3998-4007. 1999
    ..MTB32A, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during Mycobacterium spp. infection is discussed...
  6. ncbi Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis
    J R Webb
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 66:4208-14. 1998
    ..Recombinant MTB12 protein elicited in vitro proliferative responses from the peripheral blood mononuclear cells of a number of purified protein derivative-positive (PPD+) human donors but not from PPD- donors...
  7. ncbi Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells
    D M Lewinsohn
    Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington 98104, USA
    J Exp Med 187:1633-40. 1998
    ..The data suggest the possible use of nonpolymorphic MHC class Ib antigen presenting structures other than CD1...
  8. ncbi Prospects for a better vaccine against tuberculosis
    S G Reed
    Corixa Corporation, Seattle, WA 98104, USA
    Tuberculosis (Edinb) 83:213-9. 2003
    ..Thus, there is renewed optimism for the potential of developing new and improved TB vaccines...
  9. ncbi CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis
    A Campos-Neto
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 160:2037-41. 1998
    ..In contrast to original proposals, these data clearly show that protective Thl immunity can be achieved against intracellular pathogens (e.g., Mycobacterium) independently of CD40L...
  10. ncbi Fas and FasL in the homeostatic regulation of immune responses
    D H Lynch
    Immunex Corporation, Seattle, WA 98101, USA
    Immunol Today 16:569-74. 1995
    ..They discuss how dysregulation of the Fas apoptotic pathway may contribute to certain disease states, including autoimmune disease and human immunodeficiency virus (HIV)-induced depletion of CD4+ T cells...
  11. ncbi The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster
    D H Lynch
    Department of Immunobiology, Immunex Research and Development Corporation, Seattle, Washington 98101
    Immunity 1:131-6. 1994
    ..Thus, the data demonstrate that the gld phenotype is the result of a point mutation in the Fasl gene and that Fasl is part of a complex of ligands structurally related to TNF mapping within a small region of mouse chromosome 1...
  12. ncbi Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor
    R G Goodwin
    Immunex Research and Development Corporation, Seattle, Washington 98101
    Cell 73:447-56. 1993
    ..Biological characterization indicates that the cloned ligand induces the proliferation of costimulated T cells and enhances the generation of cytolytic T cells...
  13. ncbi gld/gld mice are unable to express a functional ligand for Fas
    F Ramsdell
    Department of Immunobiology, Immunex Research and Development Corporation, Seattle, WA 98101
    Eur J Immunol 24:928-33. 1994
    ..Fc fusion protein at high levels, whereas activated T cells from normal and lpr/lpr animals bind Fas.Fc efficiently. These data indicate that mice homozygous for gld are unable to express a functional ligand for Fas...
  14. ncbi Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens
    S F Ziegler
    Department of Molecular Genetics, Immunex Corp, Seattle, WA 98101
    Eur J Immunol 23:1643-8. 1993
    ..Sequence analysis showed that both mouse and human CD69 are type II membrane glycoproteins related to the NKR-P1 and Ly-49 families of natural killer cell activation molecules...
  15. ncbi Molecular and biological characterization of human 4-1BB and its ligand
    M R Alderson
    Department of Cellular Immunology, Immunex Research and Development Corporation, Seattle, WA 98101
    Eur J Immunol 24:2219-27. 1994
    ..In contrast, ligation of 4-1BB on T cell clones enhanced activation-induced cell death when triggered by engagement of the TCR/CD3 complex...
  16. ncbi Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor
    P R Baum
    Department of Gene Expression, Immunex R and D Corporation, Seattle, Washington 98101, USA
    Circ Shock 44:30-4. 1994
  17. ncbi Fas ligand mediates activation-induced cell death in human T lymphocytes
    M R Alderson
    Immunex Research and Developmental Corporation, Seattle, Washington 98101
    J Exp Med 181:71-7. 1995
    ..Fas-L antagonists inhibited AICD of T cell clones and staphylococcus enterotoxin B (SEB)-specific T cell lines. The data indicate AICD in previously stimulated T cells is mediated by Fas/Fas-L interactions...
  18. ncbi Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle
    A S Mustafa
    Department of Microbiology, Faculty of Medicine, Kuwait University, Safat
    Infect Immun 74:4566-72. 2006
    ..bovis-infected cattle in this study, Rv3616c, was significantly less frequently recognized by BCG vaccinees and could be a target to improve BCG, for example, by increasing its secretion, in a recombinant BCG vaccine...